Tirzepatide vs Retatrutide: Dual vs Triple Receptor Agonists

Introduction

The incretin receptor agonist field has advanced from single-target GLP-1 analogs to multi-receptor compounds. Tirzepatide (dual GIP/GLP-1 agonist) and retatrutide (triple GIP/GLP-1/glucagon agonist) represent successive generations of this approach. This comparison examines their structural differences, receptor pharmacology, and significance for in vitro GPCR research.

Molecular Profiles

Both peptides are engineered from a GIP backbone and share the Aib2 substitution for DPP-4 resistance and a C20 fatty diacid for albumin binding. The critical difference is retatrutide’s additional glucagon receptor (GCGR) activity, achieved through specific amino acid substitutions including alpha-methyl-L-leucine at position 13.

Receptor Pharmacology

Tirzepatide: Imbalanced Dual Agonism

Tirzepatide displays what Willard et al. (2020) characterized as “imbalanced and biased dual agonism”:

• GIPR: Full agonist equipotent to native GIP (EC₅₀ = 22.4 pM). Full efficacy for beta-arrestin recruitment and receptor internalization.
• GLP-1R: Approximately 5-fold lower binding affinity versus native GLP-1. 13-20-fold reduced cAMP potency (EC₅₀ = 934 pM). Pronounced cAMP-biased signaling with minimal beta-arrestin recruitment (<10% E_max).

This biased profile means tirzepatide is not simply a “dual agonist” — it activates each receptor with qualitatively different signaling outputs, making it a valuable pharmacological tool for studying biased agonism at class B1 GPCRs.

Retatrutide: Balanced Triple Agonism

Retatrutide functions as a full agonist at all three targets:

• GIPR: EC₅₀ = 0.064 nM (comparable to native GIP)
• GLP-1R: EC₅₀ = 0.775 nM (2.5-fold less potent than native GLP-1)
• GCGR: EC₅₀ = 5.79 nM (2.9-fold less potent than native glucagon)

The glucagon receptor component is the defining differentiator. GCGR activation engages a distinct G_s-coupled pathway in hepatocytes, activating adenylyl cyclase and downstream PKA signaling with metabolic consequences fundamentally different from the incretin receptor targets.

Structural Basis for Multi-Receptor Activity

Cryo-electron microscopy has resolved both compounds in complex with their target receptors:

• Tirzepatide: Structures at 3.1 Å (GIPR) and 2.9 Å (GLP-1R) show weaker interactions with ECL2 at GLP-1R and an alternate Trp306 rotamer, explaining reduced signaling at this receptor.
• Retatrutide: Structures across all three receptors reveal that triple agonism is achieved through conserved core interactions combined with receptor-specific conformational adaptations, particularly in extracellular loop 1 (ECL1).

Research Applications

These compounds are particularly valuable for comparative GPCR signaling studies:

• Biased signaling analysis: Tirzepatide’s imbalanced profile enables quantification of bias factors between cAMP and beta-arrestin pathways at each receptor
• Multi-receptor cross-talk: Retatrutide uniquely enables study of three receptor signaling outputs within a single experimental system
• Structure-activity relationships: Side-by-side comparison reveals how specific modifications (alphaMeL13 in retatrutide vs Aib13 in tirzepatide) differentially affect receptor selectivity

Key References

1. Willard FS, et al. (2020) Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 5(17):e140532.
2. Sun B, et al. (2022) Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci USA, 119(13):e2116506119.
3. Coskun T, et al. (2022) LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metab, 34(9):1234-1247.

All compounds discussed in this article are intended for in vitro research use only. Not for human or veterinary use.